Pharmaceuticals, Biotechnology and Life Sciences
Novartis does not need a big acquisition to kick-start growth, Chief Executive Joe Jimenez told investors on Wednesday, playing down suggestions he could use proceeds from a slew of asset sales for a significant takeover.
Novartis warned on Wednesday that price pressure on its generics drugs in the United States has intensified in the second quarter, cutting into its Sandoz division’s sales growth in the world’s largest healthcare market.
The US Food and Drug Administration (FDA) approved the expanded use of Novartis’s Zykadia (ceritinib) to include the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive, as detected by an FDA-approved test.
Novartis’ head-to-head FLAME study suggest that inhaled corticosteroids (ICS) may not be needed in some chronic obstructive pulmonary disease (COPD) patients with high blood eosinophil (a type of white blood cell) counts.
Novartises Rydapt has been approved by the FDA for the treatment of acute myeloid leukemia, and for treating adults with advanced systemic mastocytosis.
South Korea said on Thursday it has fined Swiss drugmaker Novartis 55.1 billion won ($48.80 million) for offering doctors kickbacks to recommend the company’s drugs, and also suspended insurance coverage for some of its drugs.
Johnson & Johnson <JNJ.N>, Novartis AG <NOVN.S> and Takeda Pharmaceutical Co Ltd <4502.T> have expressed interest in a buyout of the controlling stake that two families have in Brazilian drugmaker Hypermarcas SA <HYPE3.SA>, two people with knowledge of the matter said on Monday
Amgen and Novartis have formed a coalition that will be expanded and, as they hope, bring easier launching of a migraine related product, the USA-based company said late Monday.
Novartis’ has posted a first quarter net income down 15% citing a net charge related to the discontinuation of RLX030 ($-0.2 billion), as well as the decline in core operating income.
The US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to Novartis’s CTL019, an investigational chimeric antigen receptor T cell (CAR-T) therapy, for the treatment of adult patients with relapsed and refractory diffuse large B-cell lymphoma (DLBCL), who have failed two or more prior therapies.